MY106615A - Stabilized leukocyte-interferons. - Google Patents

Stabilized leukocyte-interferons.

Info

Publication number
MY106615A
MY106615A MYPI90001656A MYPI19901656A MY106615A MY 106615 A MY106615 A MY 106615A MY PI90001656 A MYPI90001656 A MY PI90001656A MY PI19901656 A MYPI19901656 A MY PI19901656A MY 106615 A MY106615 A MY 106615A
Authority
MY
Malaysia
Prior art keywords
interferons
leukocyte
stabilized
stabilized leukocyte
disaccharides
Prior art date
Application number
MYPI90001656A
Inventor
Ferro Alberto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY106615A publication Critical patent/MY106615A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE STABILIZATION OF HUMAN INTERFERON WITH DISACCHARIDES AND OPTIONALLY BILE ACIDS OR BILE ACID DERIVATIVES.
MYPI90001656A 1989-09-28 1990-09-26 Stabilized leukocyte-interferons. MY106615A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH351489 1989-09-28

Publications (1)

Publication Number Publication Date
MY106615A true MY106615A (en) 1995-06-30

Family

ID=4257630

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI90001656A MY106615A (en) 1989-09-28 1990-09-26 Stabilized leukocyte-interferons.

Country Status (26)

Country Link
EP (1) EP0420049B1 (en)
JP (1) JPH03130232A (en)
KR (1) KR910005886A (en)
CN (1) CN1050503A (en)
AR (1) AR244551A1 (en)
AT (1) ATE92334T1 (en)
AU (1) AU636653B2 (en)
CA (1) CA2024046A1 (en)
CZ (1) CZ277712B6 (en)
DD (1) DD298054A5 (en)
DE (1) DE59002183D1 (en)
FI (1) FI904756A7 (en)
HU (1) HU205555B (en)
IE (1) IE903479A1 (en)
IL (1) IL95769A0 (en)
IS (1) IS3631A7 (en)
MC (1) MC2149A1 (en)
MX (1) MX22522A (en)
MY (1) MY106615A (en)
NO (1) NO904218L (en)
NZ (1) NZ235153A (en)
PH (1) PH27531A (en)
PT (1) PT95454A (en)
RU (1) RU2008017C1 (en)
YU (1) YU184090A (en)
ZA (1) ZA907579B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028020A1 (en) * 1993-05-18 1994-12-08 Bukh Meditec A/S A method for the preparation of interferons
DK0920329T3 (en) * 1996-05-09 2003-01-27 Feronpatent Ltd Stabilization of interferons in aqueous solution with gum arabic
AU730020B2 (en) * 1997-05-09 2001-02-22 Feronpatent Limited Stabilisation of interferons in aqueous solution for manufacture of sublingually administered tablets
JP3643034B2 (en) * 1998-03-26 2005-04-27 シェーリング コーポレイション Formulation for protection of PEG-interferon alpha conjugate
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CN1175901C (en) * 1999-12-06 2004-11-17 天津华立达生物工程有限公司 Stable water solution of interferon
DE602005022895D1 (en) 2004-08-12 2010-09-23 Schering Corp STABLE PEGYLATED INTERFERON FORMULATION
DE102004048379A1 (en) 2004-10-01 2006-04-13 "Stiftung Caesar" (Center Of Advanced European Studies And Research) Spring element made of sputtered shape memory alloy
CU23432B6 (en) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech STABILIZED FORMULATIONS CONTAINING GAMMA AND ALFA INTERFERONS IN POTENTIAL PROPORTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (en) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd Purifying method of interferon
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
MA20647A1 (en) * 1985-03-25 1986-10-01 Schering Corp STABLE COMPOSITIONS BASED ON INTERFERON-GAMMA
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones

Also Published As

Publication number Publication date
HUT56284A (en) 1991-08-28
NO904218D0 (en) 1990-09-27
HU906021D0 (en) 1991-03-28
PT95454A (en) 1991-05-22
IL95769A0 (en) 1991-06-30
AU636653B2 (en) 1993-05-06
EP0420049A1 (en) 1991-04-03
DD298054A5 (en) 1992-02-06
YU184090A (en) 1992-09-07
CN1050503A (en) 1991-04-10
IE903479A1 (en) 1991-04-10
CZ277712B6 (en) 1993-03-17
ZA907579B (en) 1991-06-26
MC2149A1 (en) 1992-03-10
ATE92334T1 (en) 1993-08-15
PH27531A (en) 1993-08-18
NZ235153A (en) 1993-03-26
AU6309890A (en) 1991-04-11
CA2024046A1 (en) 1991-03-29
AR244551A1 (en) 1993-11-30
DE59002183D1 (en) 1993-09-09
CS432890A3 (en) 1992-12-16
FI904756A0 (en) 1990-09-27
HU205555B (en) 1992-05-28
IS3631A7 (en) 1991-03-29
KR910005886A (en) 1991-04-27
FI904756A7 (en) 1991-03-29
NO904218L (en) 1991-04-02
MX22522A (en) 1993-10-01
JPH03130232A (en) 1991-06-04
RU2008017C1 (en) 1994-02-28
EP0420049B1 (en) 1993-08-04

Similar Documents

Publication Publication Date Title
EP0525610A3 (en) Process for increasing the stability of enzymes and stabilized enzymes
SG139553A1 (en) 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
EP0339418A3 (en) Substituted anilides of the cycloalkyl- or heterocyclyl-carboxylic acids
AR242593A1 (en) Procedure for the preparation of total or partial esters from hyaluronic acid.
HU9202085D0 (en) Derivatives of 7-isoindolinyl-quinolone and of naphthyridone-carboxylic acid
AU6822887A (en) Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same
AU5829186A (en) 2-thio or oxo-4-aryl or heterocyclo-1,5 (2h)- pyrimidinedi-carboxylic acid diesters and 3-acyl-5- pyrimidinecarboxylic acids and esters
HU911185D0 (en) Process for the production of liposomic medical preparations with peptide-contain and deferred effect
AU6927087A (en) 1,2,3,4-tetrahydro-6-substituted-4-aryl(or heterocyclo)-3- substituted-2-thioxo(or oxo)-5-pyrimidinecarboxylic acids and esters
GR3003517T3 (en)
AU6429586A (en) Stabilization of iron in aqueous systems
EP0313517A3 (en) Aliphatic esters of 1,3,2-oxazaphospholidines
AU624079B2 (en) Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives
JPS6452780A (en) Novel glutarate compound and polymer stabilization therewith
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA864297B (en) 3-(substituted)propenylaminothiazolylcephalosporanic acids and esters thereof
AU625234B2 (en) Stabilization of glycosylized t-pa
EP0661981A1 (en) Use of hyaluronic acid and forms to prevent arterial restenosis.
AU9034291A (en) Derivates of the human parathormone fragment (1-37) in the amide or ethylamide form as active substance
AU6527390A (en) Pharmaceutical compositions for the treatment of ataxy and equilibrium problems
EP0311045A3 (en) Triglycerides having stability with lapse of time and method for stabilization thereof
EP0203528A3 (en) Cyclopentene derivatives and their use as odorants
JPS6416790A (en) 6-substituted peneem ester as anti-inflammatory drug and anti-modifying agent
IL94238A0 (en) Stabilization of carboxyl esterase
GB8917139D0 (en) Stable dispersions and the manufacture thereof